{"id":"imidazolyl-ethanamide-pentandioic-acid","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297291","moleculeType":"Small molecule","molecularWeight":"225.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The imidazole moiety and pentandioic acid (glutaric acid) backbone suggest potential involvement in amino acid metabolism, cellular energy pathways, or receptor-mediated signaling. The compound's structure indicates it may interact with metabolic enzymes or cellular transporters, but the exact molecular target and mechanism of action have not been publicly disclosed by Valenta Pharm.","oneSentence":"Imidazolyl ethanamide pentandioic acid is a small-molecule compound that likely acts as a metabolic modulator or cellular signaling agent, though its precise mechanism remains proprietary.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:34.961Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07420985","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2025-10-24","conditions":"Influenza, Acute Respiratory Viral Infection","enrollment":300},{"nctId":"NCT06859333","phase":"PHASE1","title":"Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2025-01-13","conditions":"Influenza, Viral Respiratory Infection","enrollment":36},{"nctId":"NCT06315400","phase":"PHASE4","title":"Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections","status":"UNKNOWN","sponsor":"Valenta Pharm JSC","startDate":"2023-12-19","conditions":"Influenza, Human, Acute Respiratory Infection, Common Cold","enrollment":80},{"nctId":"NCT05269290","phase":"PHASE3","title":"Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2021-09-23","conditions":"Influenza, Human, Acute Respiratory Infection, Common Cold","enrollment":240},{"nctId":"NCT05216497","phase":"PHASE3","title":"Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2021-10-06","conditions":"COVID-19","enrollment":233},{"nctId":"NCT03206346","phase":"PHASE3","title":"Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2012-01","conditions":"Influenza, Human, Acute Respiratory Infection, Viral Infection","enrollment":161},{"nctId":"NCT03191097","phase":"PHASE3","title":"Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2014-08","conditions":"Influenza, Human, Acute Respiratory Infection, Viral Infection","enrollment":310},{"nctId":"NCT03189537","phase":"PHASE3","title":"Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2010-10-03","conditions":"Influenza, Human, Acute Respiratory Infection, Common Cold","enrollment":400},{"nctId":"NCT03154515","phase":"PHASE4","title":"Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2010-01","conditions":"Common Cold, Influenza, Human, Acute Respiratory Infection","enrollment":445},{"nctId":"NCT02644018","phase":"PHASE3","title":"Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2016-01","conditions":"Common Cold, Influenza","enrollment":190}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"PNEUMONIA"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ingavirin"],"phase":"phase_3","status":"active","brandName":"Imidazolyl ethanamide pentandioic acid","genericName":"Imidazolyl ethanamide pentandioic acid","companyName":"Valenta Pharm JSC","companyId":"valenta-pharm-jsc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}